Navigation Links
The American Optometric Association and 3D@Home Consortium Sign Memorandum of Understanding
Date:3/16/2011

NEW YORK, March 16, 2011 /PRNewswire/ -- The American Optometric Association (AOA) and its 36,000 members announced its partnership with the 3D@Home Consortium, a group of more than 45 companies, to improve the understanding of 3D/S3D viewing as a safe and appropriate technology for all viewing audiences.  The parties signed a Memorandum of Understanding (MOU), stating their intent to share data and jointly promote vision health utilizing stereoscopic 3D displays.

The two groups signed the agreement following the "3D Vision and Health Symposium," organized by the two organizations and hosted by the State University of New York College of Optometry. The event was sponsored by Marchon3D.

The cooperative relationship will be a conduit for the exchange of the most current information and research.  Both the AOA and the 3D@Home Consortium acknowledge vision and eye health may enhance consumers' abilities to view 3D/S3D images, and ultimately increase their use of such technology.  The two groups will collaborate in the development of common interest strategies, exchange of ideas, and shared best practices.

With the range of new 3D products now available for home use, the quality of viewing is not based solely on image related aspects but is also tied explicitly to human vision development and the human perceptual experience.  Potential projects covered by the MOU include: 1) enhanced public and professional communication; 2) development and design of 3D/S3D based vision risk assessment tools; 3) development and design of applied therapies; 4) providing new integrated efforts for quality improvement and evaluation; and 5) improved public health and vision and eye health.

"AOA, representing America's family eye doctors, will be of great assistance to the 3D@Home Consortium in broadening their understanding of the human visual system," said Dori Carlson, OD, President-Elect of the AOA. "We also know that 3D viewing may help discover subtle vision disorders in both children and adults, that, left uncorrected, interfere with the 3D viewing experience, and even result in the '3Ds of 3D viewing'—discomfort, dizziness, or lack of depth."

The 3D@Home Consortium, working to accelerate the adoption of 3D/S3D in the home, provides a coordinated industry voice in 3D technology to both professionals and consumers.  "By working together, the 3D@Home Consortium and the AOA can leverage the rich diversity of our organizations' membership in conducting the critical research on stereographic imagery and its impact on the human visual system. This information is a needed component for the applications of 3D in entertainment as well as commercial, industrial and education. Even more important is how we explore various ways this same research and technology can detect and help treat vision problems undetected in the past," said Rick Dean, Chairman of the 3D@Home Consortium.

Both groups will be encouraging their constituents to incorporate the use of stereoscopic testing and educational materials in their products, helping the public build an appreciation for the importance of optometry-delivered vision and eye health care, as well as the importance of yearly comprehensive eye exams.

For more information, visit www.3Deyehealth.org.

About the American Optometric Association (AOA):The American Optometric Association represents approximately 36,000 doctors of optometry, optometry students and paraoptometric assistants and technicians. Optometrists serve patients in nearly 6,500 communities across the country, and in 3,500 of those communities are the only eye doctors. Doctors of optometry provide two-thirds of all primary eye care in the United States.

American Optometric Association doctors of optometry are highly qualified, trained doctors on the frontline of eye and vision care who examine, diagnose, treat and manage diseases and disorders of the eye. In addition to providing eye and vision care, optometrists play a major role in a patient's overall health and well-being by detecting systemic diseases such as diabetes and hypertension.

Prior to optometry school, optometrists typically complete four years of undergraduate study, culminating in a bachelor's degree. Required undergraduate coursework for pre-optometry students is extensive and covers a wide variety of advanced health, science and mathematics. Optometry school consists of four years of post-graduate, doctoral study concentrating on both the eye and systemic health. In addition to their formal training, doctors of optometry must undergo annual continuing education to stay current on the latest standards of care. For more information, visit www.aoa.org.

About The 3D@Home Consortium:

3D@Home is a global, not-for-profit membership organization formed to accelerate the adoption of 3D into homes worldwide.  The group's membership list includes large and small multinational companies whose products and services span the 3D eco-system, including, 3D creation and capture, production, post-production, compliance testing, transmission, and 3D display, playback and accessories.   For more information, visit http://www.3DatHome.org.  Contact:  Susan Thomas314-983-4263slthomas@aoa.org
'/>"/>

SOURCE American Optometric Association; 3D@Home Consortium
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. American Botanical Council Announces Recipients of Botanical Excellence Awards
2. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
3. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
4. Amarin Announces Proposed Public Offering of American Depositary Shares
5. Argus Launches North American Wood Chip Price Assessments
6. Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF
7. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
8. New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
9. Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
10. Enerkem adds two new executive roles to growing North American presence
11. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):